Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nanotech bill sails through House

This article was originally published in The Tan Sheet

Executive Summary

The House Feb. 11 passes the National Nanotechnology Initiative Amendments Act, H.R. 554, to direct federal nanotechnology research, strengthen public-private partnerships through industry liaison groups and prioritize protecting public health and safety. An identical version of the bill cleared the House in 2008, but failed in the Senate (1"The Tan Sheet" Feb. 2, 2009, p. 16). In a same-day release, bill sponsor and Science and Technology Committee Chairman Bart Gordon says the legislation "will reduce the current uncertainty that inhibits commercial development of nanotechnology and will provide a sound basis for future rulemaking." The Tennessee Democrat adds that nanotechnology could be a $2.6 trillion industry by 2014

You may also be interested in...

House Shows Nanotech Safety Interest With Bill To Sharpen Federal Plan

The House Committee on Science and Technology will consider legislation crafted to provide strategic direction to the federal research program for nanotechnology

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts